Skip to content
Apogee Biotechnology Corporation

Apogee Biotechnology Corporation

  • Welcome
  • News
  • Technology
  • Lead Compound
  • Contact Us / Policies

Phase 2/3 Clinical Trial with Opaganib for COVID-19 Submitted

Posted bylwm100 June 11, 2020June 11, 2020 Leave a comment on Phase 2/3 Clinical Trial with Opaganib for COVID-19 Submitted

https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=16265

Posted bylwm100June 11, 2020June 11, 2020Posted inUncategorized

Post navigation

Previous Post Previous post:
Opaganib (ABC294640) Successfully Treats Patients with COVID-19 in Israel, Clinical Trial Approved in the U.S.
Next Post Next post:
Phase 2/3 Study with opaganib approved in UK for COVID-19

Leave a comment

Cancel reply

Your email address will not be published. Required fields are marked *

Apogee Biotechnology Corporation, Proudly powered by WordPress.